Document is current
Any future updates will be listed below
-
Authors
Crummer, Elliott
Cohen, Joshua T.
Rosmarin, David
Lin, Pei-Jung
-
Funding
Funding for this research was provided by:
Incyte Corporation
- License Information
-
More Information
Article History
Received: 10 June 2024
Revised: 18 July 2024
Accepted: 5 August 2024
First Online: 22 August 2024
Declarations
:
: David Rosmarin has consulted, spoken for, or conducted trials for the following companies: AbbVie, Abcuro, Almirall, AltruBio, Amgen, Arena, Astria, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Galderma, Incyte, Janssen, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT, Regeneron, Recludix, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, VielaBio, Zura Bio; Joshua T. Cohen has consulted or received grant support from the following life sciences companies and groups: Abbvie, Amgen, Analysis Group, Astra Zeneca, Biogen, Brystol Myers Squibb, Eli Lily, Giliead, IQvia, Johnson and Johnson, Lundbeck, Merck, Moderna, National Pharmaceutical Council, No Patient Left Behind, Novartis, Partnership for Health Analytic Research, Patient Square Capital, Pfizer, Pharmerit, PhRMA Foundation, Precision Health Economics, RA Capital, Regeneron, Sage, Sanofi, Sarepta, Vir Bio; Elliott Crummer and Pei-Jung Lin have no relevant competing interests to declare. IRB Approval Status. This study (STUDY00003692) has been deemed not to be human subjects research by the Tufts Health Sciences Institutional Review Board.
